[128] By contrast, other DAT inhibitors including bupropion have not been noticed to show this influence.[129] These observations have prompted the hypothesis that methylphenidate may act as a "DAT inverse agonist" or "negative allosteric modifier from the DAT" by reversing the direction in the dopamine efflux because of the DAT at increased dosage